| EDITORIALS |
| 554 | Vitamin D deficiency can impair respiratory health
|
| 556 | Pulmonary hypertension in combined pulmonary fibrosis and emphysema: A tale of two cities
|
| 558 | Picking the winners: Outcome prediction in pleural disease
|
| 560 | Three-dimensional facial phenotyping in obstructive sleep apnoea
|
| COMMENTARIES |
| 562 | Difficulties of predicting the timing, size and severity of influenza seasons
|
| 564 | An alternative approach to the current diagnostic guidelines for fibrotic interstitial lung disease
|
| INVITED REVIEW SERIES |
| Tuberculosis Updates 2018 |
| 567 | Epidemiological, clinical and mechanistic perspectives of tuberculosis in older people
|
| ORIGINAL ARTICLES |
| Asthma and Allergy |
| 576 |
Vitamin D and respiratory health in the Busselton Healthy Ageing Study
Siobhain Mulrennan, Matthew Knuiman, John P Walsh, Jennie Hui, Michael Hunter, Mark Divitini, Kun Zhu, Brian R Cooke, Arthur W (Bill) Musk, Alan James
10.1111/resp.13239
Vitamin D in relation to respiratory disease was examined by cross-sectional analysis of a large community-based sample. Low levels of serum 25-hydroxyvitamin D were independently associated with asthma, bronchitis, wheeze and chest tightness after three levels of adjustment for potential confounders. Higher vitamin D levels were associated with higher levels of lung function. |
| COPD |
| 583 | Patterns of use of long-acting bronchodilators in patients with COPD: A nationwide follow-up study of new users in New Zealand
Lianne Parkin, David Barson, Jiaxu Zeng, Simon Horsburgh, Katrina Sharples, Jack Dummer
10.1111/resp.13235
In this nationwide follow-up study of patients initiating long-acting beta2-agonist (LABA) and/or longacting muscarinic antagonist therapy (LAMA) for chronic obstructive pulmonary disease, the most common first regimen was a LABA with an inhaled corticosteroid (ICS). ICS use was inconsistent with guidelines. There were complex therapy patterns, including periods of non-use. |
| Interstitial Lung Disease |
| 593 |
Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema
Joseph Jacob, Brian J Bartholmai, Srinivasan Rajagopalan, Ronald Karwoski, Arjun Nair, Simon L F Walsh, Joseph Barnett, Gary Cross, Eoin P Judge, Maria Kokosi, Elisabetta Renzoni, Toby M Maher, Athol U Wells
10.1111/resp.13231
In combined pulmonary fibrosis and emphysema (CPFE), the likelihood of having pulmonary hypertension (PHT) is explained by the summed baseline computed tomography (CT) extents of interstitial lung disease and emphysema. There is no synergistic effect in CPFE increasing the likelihood of PHT. CPFE is therefore not associated with a malignant microvascular phenotype. |
| 600 | Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality
Bryan T Kelly, Teng Moua
10.1111/resp.13254
Interstitial pneumonia with autoimmune feature (IPAF) criteria were recently established to clarify research definitions for interstitial lung disease (ILD) patients with features of autoimmune disease. Our study found these criteria encompassed the majority of patients previously diagnosed as UCTD-ILD and did not exclude radiological or histological usual interstitial pneumonia (UIP) (IPAF with UIP features), whose survival was indistinguishable from idiopathic pulmonary fibrosis (IPF). |
| 606 | Co-morbidity and mortality among patients with interstitial lung diseases: A population-based study
Ole Hilberg, Elisabeth Bendstrup, Anders Løkke, Rikke Ibsen Andreas, Fløe Charlotte Hyldgaard
10.1111/resp.13234
This study reports the findings in a large population-based interstitial lung disease (ILD) cohort identified from national medical registries. Mortality was increased among patients with ILD at all levels of co-morbidities, but the difference in mortality between ILD patients and matched controls decreases with increasing burden of co-morbidities. |
| Pleural Disease |
| 613 | Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience
Joke Leemans, Christophe Dooms, Vincent Ninane, Jonas Yserbyt
10.1111/resp.13252
Identifying factors determining the success of talc pleurodesis in malignant pleurisy could guide clinical decision-making. This observational survey shows that a delay in referral of symptomatic patients for pleurodesis might compromise its success. Ultrasonic assessment of potential lung expansion can help to identify trapped lung. |
| Sleep and Ventilation |
| 618 | Three-dimensional photography for the evaluation of facial profiles in obstructive sleep apnoea
Shih-Wei Lin, Kate Sutherland, Yu-Fang Liao, Peter A Cistulli, Li-Pang Chuang, Yu-Ting Chou, Chih-Hao Chang, Chung-Shu Lee, Li-Fu Li, Ning-Hung Chen
10.1111/resp.13261
Craniofacial structure is an important determinant of obstructive sleep apnoea (OSA) syndrome risk. Rapid quantitative analysis of facial surface morphology is needed for large population-based studies. Radiation-free three-dimensional stereo-photogrammetry provides accurate craniofacial measurements in patients with OSA which are highly concordant with those obtained by computed tomography. |
| LETTER FROM ASIA-PACIFIC REGION |
| 626 | Letter from Bangladesh
|
| YEAR IN REVIEW |
| 628 | Year in review 2017: Interventional pulmonology, lung cancer, pleural disease and respiratory infections
Lonny Yarmus, Phan T Nguyen, Kristina Montemayor, Mark Jennings, Brett Bade, Majid Shafiq, Gerard Silvestri, Daniel Steinfort
10.1111/resp.13306 |
| CORRESPONDENCE |
| 636 | M/XDR-TB treatment perspective: How to avoid mountains of pills via digital technologies
Andrii Dudnyk MD, PhD, Matthew Burman MD, Ludmyla Kulyk MD, PhD, Olena Rzhepishevska PhD
10.1111/resp.13311 |
| 637 | M/XDR-TB treatment perspective: How to avoid mountains of pills via digital technologies – Reply
Keertan Dheda MBBCh(Wits), FCP(SA), FCCP, PhD(Lond), FRCP(Lond), on behalf of all authors
10.1111/resp.13317 |
